Here's Why Intellia Therapeutics Sank as Much as 17.7% Today
Shares of CRISPR gene-editing biopharma Intellia Therapeutics (NASDAQ: NTLA) dropped nearly 18% today after the company announced a major public share offering to increase its cash balance. The biopharma will offer 6.25 million shares, with the option to purchase an additional 937,500 shares, at $24 apiece.
The good news is that the share offering will provide gross proceeds of up to $170 million. The bad news is that the share offering will dilute existing shareholders by up to 20%. Overall, this was a great move by management.
As of 11:56 a.m. EDT, the stock had settled to a 15.2% loss.
Source: Fool.com
Intellia Therapeutics Inc Aktie
18,68 €
0,52 %
Die Community neigt bei Intellia Therapeutics Inc zu Buy-Einschätzungen, mit einigen mehr als Sell-Einschätzungen.
Mit einem Community-Kursziel von 60 € für Intellia Therapeutics Inc wird ein starkes Wachstumspotenzial gegenüber dem aktuellen Kurs von 18.68 € gesehen.
